g-Butyrolactones: Streptomyces signalling molecules regulating antibiotic production and differentiation Eriko Takano 1, 2 Small signalling molecules called g-butyrolactones are mainly produced by Streptomyces species in which they regulate antibiotic production and morphological differentiation. Their molecular mechanism of action has recently been unravelled in several streptomycetes, revealing a diverse and complex system. g-Butyrolactones and their receptors also occur in some other Actinobacteria, suggesting that this is a general regulatory system for antibiotic production. The gbutyrolactones bind to receptors, many of which are involved in regulation of specific antibiotic biosynthesis clusters. The importance of understanding how secondary metabolites are regulated and how environmental and physiological signals are sensed highlights the relevance of studying this system.
Introduction
Bacterial cell-to-cell communication by small signalling molecules, in particular N-acyl-homoserine lactones (AHLs) in proteobacteria, has been studied intensively over the past decade [1 -3 ] . However, the first signalling molecules to be identified were the g-butyrolactones from Streptomyces in the 1960s, and these also have recently seen a flowering of interest [4 ,5-7] .
Streptomyces is a genus of Gram-positive soil bacteria with complex morphological development. It produces more than 70% of commercially available antibiotics [8] . Pioneer work by Khokhlov [9] identified a g-butyrolactone from Streptomyces griseus (also known as autoregulatory factor or A-factor) that induced streptomycin production and sporulation. The structures of fourteen 2,3-disubstituted g-butyrolactones that are from seven Streptomyces species have been determined so far, and they differ in length, branching and the stereochemistry of their fatty acid side-chain ( Figure 1 ) [5] [6] [7] . All of these factors regulate the production of antibiotics, are effective in nano Molar concentrations and in some cases they regulate differentiation. The g-butyrolactones bind to cytoplasmic receptor proteins (e.g. ArpA in S. griseus) and inhibit their binding to specific DNA targets. Most of these receptor proteins act as repressors, so that binding to g-butyrolactones induces expression of the target genes. Each receptor protein is highly specific for its cognate gbutyrolactone [4 ,5-7] . Biosynthesis of g-butyrolactones is not well understood, but seems to require a member of a protein family, the archetype of which is AfsA in S. griseus. The chemical structure of g-butyrolactones is similar to that of AHLs except for the carbon side-chain ( Figure 1) . However, the g-butyrolactone receptors do not bind to AHL, and AHL receptors to not bind to g-butyrolactones (E Takano, unpublished); this is also confirmed by the low similarity of both signalling molecule receptors. The functions of the signalling molecules also seems to differ as AHLs have very diverse properties [1 -3 ] , whereas the g-butyrolactones mainly regulate the production of antibiotics and differentiation [4 ,5-7] . Furthermore, the synthesis of the signalling molecule also differs as LuxI, the AHL synthase, is not similar to AfsA.
There are many reviews on the A-factor system from S. griseus and the virginiae butanolide (VB) system from Streptomyces virginiae [4 ,5-7] . Here, I focus mainly on new insights into different aspects of the g-butyrolactone regulatory system, especially in Streptomyces coelicolor, and demonstrate its diversity.
The S. coelicolor butanolide system
The structures of S. coelicolor g-butyrolactones active in the A-factor bioassay were proposed in the 1980s [10] . Recently, three g-butyrolactones have been determined, and more are anticipated to be determined from highperformance liquid chromatography (HPLC) analysis and bioassays [11] (E Takano, unpublished) ( Figure 1 ). The most abundant is S. coelicolor butanolide 1 (SCB1), reported previously to stimulate actinorhodin (Act) and undecylprodigiosin (Red) production. The SCBs are only active in a narrow concentration range of 0.25-0.5 mM, suggesting strictly controlled expression and production of these small molecules. The SCBs are more stable than A-factor, possibly because of the hydroxyl group at C6, and can still be found more than 12 h into stationary phase. Degradation of SCBs has been observed only in some rich media (E Takano, unpublished). Whether this is as a result of active degradation or of a pH change in the cells that causes the lactone ring to open is not certain. SCBs are produced at late transition phase when expression of scbA, a gene involved in SCB synthesis (afsA homologue), is induced rather than accumulating from early exponential phase as in the A-factor system. Thus the scbA deletion mutant does not produce any of the gbutyrolactones which have antibiotic-stimulatory activity [12] . Along with scbA, an arpA-like g-butyrolactone receptor gene, scbR, has been characterised. ScbR binds to its own promoter and to that of the adjacent diverging scbA, thus regulating production of SCBs [12] . Corresponding receptor protein targets have not been clearly identified in other systems, although homologues of both genes exist in all of them. Microarray analysis revealed that ScbR also represses the pathway-specific activator gene, kasO, which activates a biosynthetic gene cluster (kas, located next to scbR) that codes for synthesis of an unknown polyketide [13 ] . In the scbR mutant, expression of most of the genes in the kas cluster was greatly increased. The DNA sequence of two ScbR target sites, shown to be repressor sites, was completely conserved [13 ] . However the proposed consensus target sequences for g-butyrolactone receptors all have considerable variability [5] . From the ScbR binding consensus sequence, only one other conserved sequence was identified upstream of orfB, two genes away from scbR. The role of this gene is still under investigation. The SCB system is summarised as a model in Figure 2 .
An alternative method for g-butyrolactone determination, and g-butyrolactones from non-streptomycetes Structural determination of a new g-butyrolactone was last reported in 2001 [11] . This is surprising as there are many reports of g-butyrolactone receptors in the last three years (see below). The very small amount of g-butyrolactones produced in Streptomyces cultures and the limited ability to detect the signalling molecules by bioassays might be the reason for the paucity of more structural determinations.
Recently, Yang et al. [14 ] reported an alternative detection system using ScbR, the receptor protein and electrospray tandem mass spectrometry (ESI-MS/MS). This method does not require large amounts of cultures and might be useful for those strains where the g-butyrolactone receptors have already been identified. However, with this method, only SCB1 was identified from S. coelicolor, even though at least two other g-butyrolactones also bind to ScbR (E Takano, unpublished). Possibly, SCB1 was the most abundant g-butyrolactone, and this might explain why the others were not identified. g-Butyrolactones were also identified from non-Streptomyces actinomycetes that produce commercially important 288 Ecology and industrial microbiology Figure 1 Chemical structures of g-butyrolactones from Streptomyces and C4-homoserine lactone from Pseudomonas aeruginosa. The name of the signalling molecules appear in bold, and the antibiotic that it effects or its other functions are shown in brackets.
antibiotics [15] . Amycolatopsis mediterranei that produces rifamycin, and Actinoplanes teichomyceticus, a teicoplanin producer, were both found to produce g-butyrolactones using a bioassay for IM-2 of Streptomyces lavendulae and VB of S. virginiae, respectively. In the same report, g-butyrolactone receptor proteins were also identified from A. mediterranei, A. teichomyceticus, and Micromonospora echinospora, a gentamicin producer, binding to IM-2, VB or SCB1, and SCB1 respectively. This report suggests that g-butyrolactone signalling systems are widespread regulators of antibiotic production in actinomycetes.
g-Butyrolactone synthesis: are AfsA homologues enzymes or regulators?
There is an unresolved contradiction concerning the function of AfsA and its S. virginiae homologue BarX. AfsA, a putative A-factor biosynthetic gene, has been reported to condense a glycerol derivative and a b-keto acid (derived from fatty acid biosynthesis) to produce g-butyrolactones [16] , whereas BarX has been reported to stabilise receptor-DNA binding, suggesting a regulatory function [17] . There are several reports of AfsA homologues (Table 1) , but no clear function has been assigned to any for these and in vitro synthesis of g-butyrolactones has not yet been found. Furthermore, no homologues have been identified in the DNA or protein databases for this family of proteins, apart from one partial homologue (see below).
All afsA-family genes -apart from afsA itself -are located either very close to, or in, antibiotic biosynthetic clusters, and many are either adjacent or close to, and sometimes divergent from, their respective g-butyrolactone receptor gene (Table 1) . This is the case for the gene-product of scbA, the AfsA homologue in S. coelicolor, which is located near a recently identified polyketide biosynthesis cluster [13 ] and is divergent from scbR [12] . However, ScbA might possess both regulatory and enzymatic functions. By microarray analysis, many primary metabolic and regulatory genes were identified which are differentially expressed when the scbA mutant was compared to the wild type in early exponential phase (E Takano, unpublished). Furthermore, mutagenesis of a conserved amino acid residue of ScbA, selected using computer-assisted active-site predictions, eliminated g-butyrolactone production (E Takano, unpublished). It is intriguing that a gene product from Gloeobacter violaceus PCC 7421 (a cyanobacterium), which is annotated as a polyketide synthase because most of the domains in the protein resemble acyl transferase domains and phosphopantetheine attachment sites, contains an Afs domain (Pfam03756), indicating that the protein has an enzymatic role. Although a pathway for g-butyrolactone biosynthesis was suggested in 1992 [18] , the only further Schematic model of the SCB system in S. coelicolor. ScbR (light-blue ovals) binds as a dimer to 4 targets sites. One repressor site is in front of its own promoter (scbRp) and two other repressor sites are in front of the kasO (pathway-specific activator) promoter (kasOp). In all cases, the g-butyrolactones (SCBs; red triangles) bind to ScbR (deep-blue ovals with triangle) and relieves the repression. ScbA (pink circles) is involved in production of SCBs and also is required along with SCBs and ScbR for its own expression (scbAp, the scbA promoter). This precise mechanism is under investigation (shown as '?'). ScbR might regulate other genes which could in turn regulate the production of Act and Red. KasO actively regulates the transcription of the kas gene cluster. Arrows denote activation and lines with a bar denote repression.
report of a proven g-butyrolactone biosynthetic step involves BarS1, which catalyses the last reduction in C6 of VB biosynthesis [6, 19] .
g-Butyrolactone receptors
Are they pathway-specific regulators?
The enormous increase in the number of g-butyrolactone receptor homologues that have been identified in the past three years (Table 2 ) reflects the fact that the nucleotide sequences of many gene clusters that encode production of secondary metabolites have recently become available, including those in the complete genome sequences of S. coelicolor [20] and Streptomyces avermitilis [21] . At least 22 out of 33 genes encoding homologues of g-butyrolactone receptors are located close to antibiotic biosynthesis genes and/or have been shown to regulate antibiotic production [13 ] . Thus, it seems that g-butyrolactones are strongly associated with the regulation of antibiotic production and that most of the g-butyrolactone receptors could be pathway-specific. It is interesting that, for the first time, a receptor protein from a non-streptomycete has been cloned and disrupted with a positive effect on antibiotic production [22 ] .
Several mutagenesis studies of g-butyrolactone receptors have been reported (Table 2) . In most cases, deletion of the receptor caused overproduction of an antibiotic, as in the paradigm S. griseus system. However, for some receptor genes, antibiotic production was delayed or abolished [23] [24] [25] . In S. coelicolor, it was initially thought that deletion of the receptor genes delayed synthesis of Act and Red, but the recent finding that the scbR-linked kas cluster was overexpressed in the scbR mutant [13 ] suggests that the g-butyrolactone receptor primarily represses biosynthesis of the kas product, and that production of other antibiotics might then be indirectly affected by abundance of precursors, or by other unknown effects on the expression of the other antibiotic biosynthesis genes.
The role of multiple receptor genes
In many streptomycetes multiple g-butyrolactone receptor homologues exist, and in some they all are located in antibiotic biosynthesis gene clusters [26 ,27,28] . The best characterised examples of such systems are the VB system [29] [30] [31] and the tylosin system from Streptomyces fradie [32] [33] [34] . In both cases, studies with mutants showed that a main receptor represses other homologues, forming a regulatory cascade leading to antibiotic production. However, in neither case is there biochemical evidence showing direct regulation by these main receptors on the homologues.
In S. coelicolor, three receptors, other than ScbR, have been identified, as well as ScbR2. Previous reports indicate that cprA and cprB mutants show that when mutated separately, the resulting mutants have the opposite phenotype in both antibiotic production and sporulation, i.e. the cprA mutant has reduced antibiotic production and delayed sporulation, whereas the cprB mutant overproduces antibiotics and sporulates earlier. Therefore, CprA is an activator for both antibiotic production and sporulation whereas CprB is a repressor. [35] . We independently mutated cprA and cprB to find that there was no obvious phenotype in these mutants. However, a cprAB double deletion mutant was unable to sporulate (E Takano, unpublished). These differences in the mutant phenotypes in different laboratories might be as a result of the different parent strains that were used for the mutagenesis. The roles of CprA, CprB and ScbR2 still need to be clarified: preliminary evidence suggests that ScbR2 is involved in regulation of the Kas cluster, of which scbR2 forms a part; cprB is located two genes upstream of the geosmin biosynthesis gene cluster [20, 36] , but its effect on geosmin production has not yet been determined; and cprA is not located close to a known antibiotic biosynthesis gene cluster. Unlike the VB system and that of tylosin, ScbR does not directly regulate expression of the other receptor homologues [13] unpublished); this is intriguing, what does regulate expression of these homologues? Understanding this will, in turn, aid in understanding of the role of these homologues in S. coelicolor.
Multiple proteins can bind to the g-butyrolactone receptor binding site A g-butyrolactone receptor homologue from S. clavuligerus was identified in two different laboratories (this gene has two different names, scaR and brp) [37, 38 ] . Interestingly, the identified target sequence for the receptor that is upstream of the pathway-specific regulator has been shown to bind to another protein [38 ] . This report is a first example of multiple proteins binding to a gbutyrolactone-receptor target sequence. The determination of the second protein is of extreme interest.
Crystal structure of the g-butyrolactone receptor
The first crystal structure of a g-butyrolactone receptor, CprB from S. coelicolor, was determined by Natsume et al. [39 ] . Two forms of the structure were obtained, both dimers, and the overall structure resembles that of the TetR family. The large cavity found in the regulatory domain is probably the g-butyrolactone binding pocket, with conserved amino acid residues within the cavity. It is thought that the conformation of the protein changes with binding of the g-butyrolactones, causing the DNA-binding domain to relocate, and CprB to dissociate from the DNA. This crystal structure will aid in understanding the structural similarity of the g-butyrolactone receptor homologues. However, it is worth noting that CprB has not biochemically been shown to bind to a S. coelicolor DNA sequence or a g-butyrolactone. Further crystal studies of receptors known to bind to DNA with and without cognate g-butyrolactones will be of interest.
Conclusions
g-Butyrolactone signalling has been dominated by the Afactor system in S. griseus because it was the first signalling cascade into antibiotic production to be reported [5] . Recently, as many reports on g-butyrolactone systems in different actinomycetes have appeared, the diversity and the complexity of the g-butyrolactone signalling system are becoming clear [40] .
The detailed mechanisms of the g-butyrolactone signalling system -these are synthesis, receptor specificity to DNA sequences, multiple signals and receptors, degradation, the effect of g-butyrolactone on primary metabolism and antibiotic production, and signalling cascades -are just a few of the aspects that need further detailed study. We have only seen the tip of this iceberg. We need to fully understand the role of these small signalling molecules, whether it is to regulate and coordinate antibiotic production, to sense environmental and physiological signals, or to communicate or coordinate with other bacteria or within the multiple compartments of the same organism. With increasing interest -as seen by the number of publications on the topic, boosted by the genome sequences of S. coelicolor, S. avermitilis and other streptomycetes -many of these questions will surely be answered in the near future.
